Effect of diabetes on survival in myeloma may differ by race: Study
While diabetes is more frequent among Black people than white people, it’s associated with poorer survival outcomes in white people with multiple myeloma, a…
News
Phase 3 trial of Venclexta for hard-to-treat myeloma misses main goal
People with hard-to-treat multiple myeloma given a regimen of Venclexta (venetoclax) plus dexamethasone lived longer than those treated with Pomalyst (pomalidomide) plus the…
Vaccine may help boost response to stem cell transplant: Phase 1 trial
A cell-based vaccine designed to promote immune responses against survivin, a protein that helps tumor cells survive and expand, was found to be safe and…
Phase 1b trial enrolling to test continuous low-dose lenalidomide
The Gabrail Cancer Center (GCC) in Canton, Ohio is the first site to open in a Phase 1b clinical trial that’s evaluating STAR-LLD, Starton…
Aphexda approved in US to improve autologous stem cell transplants
The U.S. has approved BioLineRx’s Aphexda (motixafortide) in combination with filgrastim (G-CSF) to improve the process of autologous hematopoietic stem cell transplant (AHSCT)…
Some myeloma cells may mutate to resist T-cell therapies: Study
Some multiple myeloma cells acquire mutations that allow them to act in disguise and to escape the effects of T-cell therapies, according to a…
Spotlight shines on blood cancer this September awareness month
Blood Cancer Awareness Month, observed globally every September, seeks to raise awareness of all blood malignancies — there’s one case of blood cancer diagnosed…
Elranatamab, now Elrexfio, approved for hard-to-treat myeloma
The U.S. Food and Drug Administration (FDA) has granted conditional approval to Pfizer‘s elranatamab — an antibody therapy to be marketed under the brand…
1st human trial to test LBL-034 for hard-to-treat myeloma in US, China
Nanjing Leads Biolabs is planning to launch a first-in-human clinical trial to test LBL-034, an antibody-based therapy designed to trigger the immune system to…
Myeloma cells in lab, mice killed with nanoparticle-delivered RNA
Researchers at Tel Aviv University in Israel have developed a new nanoparticle system that can deliver RNA-based therapies designed to kill myeloma cells in…
